EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced the online publication of the results from the CLARITY(1) Phase III trial using Cladribine Tablets (EMD Serono’s proprietary investigational oral formulation of cladribine) in The New England Journal of Medicine(2). The CLARITY study was a two-year (96-week), randomized, double-blind, placebo-controlled Phase III trial of Cladribine Tablets in 1,326 people with relapsing-remitting multiple sclerosis (MS)…

Here is the original post: 
Two-Year Results From CLARITY Study With Cladribine Tablets In Multiple Sclerosis Published In The New England Journal Of Medicine

You may also like:

• FDA Approves Ampyra To Improve Walking In Adults With Multiple Sclerosis
• Neuralstem Announces First Patient Treated In ALS Stem Cell Trial
• New Approach To Postsurgical Monitoring After Surgery Could Keep Patients Out Of ICUs
• Two-Year Results From CLARITY Study With Cladribine Tablets In Multiple Sclerosis Published In The New England Journal Of Medicine
• Repros Requests Type B Meeting With FDA To Discuss Phase III Protocols For Androxal(R)
• Novartis Tasigna® Trial Shows Superior Results To Glivec® In Patients With Early-stage Chronic Myeloid Leukemia
• Biogen Idec’s Oral Compound BG-12 Achieves Development Milestones In MS And RA
• Celsion’s Global Phase III ThermoDox(R) Trial Approved By State Food And Drug Administration In China
• Drug Option For Patients Beginning HIV Treatment Studied
• Nycomed Announces FDA Filing For Daxas(R) In COPD